Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Luo, Peng  [Clear All Filters]
2024
Zhang K, Liu X, Luo P, Li Z, Zhao H, Li D, Liu Z, Zhang B, Shen C. Upregulation of IDO gene expression reduces the immunogenicity of epidermal cells and strengthens the immune protection of epidermal cells during transplantation treatment of wounds. Transpl Immunol. 2024:101987.
2023
Huang Y, Han F, Li J, Li Y, Gao J, Lai L, Luo P, Su M, Hu R. BTN2A2-Ig protein inhibits the differentiation of pathogenic Th17 cells and attenuates EAE in mice. Immunol Lett. 2023.
Zhao Y, Li Y, He J, Li M, Yao X, Yang H, Luo Z, Luo P, Su M. Nanointegrative Glycoengineering-Activated Necroptosis of Triple Negative Breast Cancer Stem Cells Enables Self-Amplifiable Immunotherapy for Systemic Tumor Rejection. Adv Healthc Mater. 2023:e2303337.
Xia K, Wang F, Tan Z, Zhang S, Lai X, Ou W, Yang C, Chen H, Peng H, Luo P, et al. Precise Correction of Lhcgr Mutation in Stem Leydig Cells by Prime Editing Rescues Hereditary Primary Hypogonadism in Mice. Adv Sci (Weinh). 2023:e2300993.
Luo P, Shi Z, He C, Chen G, Feng J, Zhu L, Song X. Predicting the Clinical Outcome of Triple-Negative Breast Cancer Based on the Gene Expression Characteristics of Necroptosis and Different Molecular Subtypes. Stem Cells Int. 2023;2023:8427767.
2022
Xia K, Wang F, Lai X, Dong L, Luo P, Zhang S, Yang C, Chen H, Ma Y, Huang W, et al. AAV-mediated gene therapy produces fertile offspring in the Lhcgr-deficient mouse model of Leydig cell failure. Cell Rep Med. 2022:100792.
2021
Luo P, Feng X, Deng R, Wang F, Zhang Y, Li X, Zhang M, Wan Z, Xiang APeng, Xia K, et al. An autofluorescence-based isolation of Leydig cells for testosterone deficiency treatment. Mol Cell Endocrinol. 2021:111389.
2019
Jiang Y, Zhou J, Hou D, Luo P, Gao H, Ma Y, Chen Y-S, Li L, Zou D, Zhang H, et al. Prosaposin is a biomarker of mesenchymal glioblastoma and regulates mesenchymal transition through the TGF-β1/Smad signaling pathway. J Pathol. 2019.